Melanoma Vaccine: What Do Phase 3 Results Mean?

What did the personalized melanoma vaccine trial find?

On August 19, Merck and Moderna announced positive initial results from INTerpath-001, a randomized phase 3 trial involving people with completely removed stage IIB–IV melanoma. The study compared the personalized vaccine intismeran autogene, also called V940 or mRNA-4157, plus pembrolizumab with placebo plus pembrolizumab. According to the companies, the combination met its primary recurrence-free survival endpoint and its key secondary distant metastasis-free survival endpoint. Overall survival remains under investigation. [Merck and Moderna trial announcement](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

The earlier KEYNOTE-942 phase 2b trial provides separately reported numerical context. It randomized 157 patients, with 107 assigned to combination treatment and 50 to pembrolizumab alone. At a median follow-up of approximately five years, researchers reported a hazard ratio of 0.51 for recurrence or death, corresponding to a 49% lower relative hazard. That figure comes from the earlier trial and does not describe the new phase 3 result. It also does not mean that 49 additional patients out of every 100 were cured. [KEYNOTE-942 five-year publication](https://ascopubs.org/doi/10.1200/JCO-26-00835)

How does a personalized mRNA cancer vaccine work?

Cancer cells acquire genetic changes that can create distinctive protein fragments called neoantigens. Intismeran is designed around selected targets from each patient's tumor, using messenger RNA to provide instructions for producing those targets and stimulating an immune response. The intended result is a population of immune cells better able to recognize cancer carrying the same features. This individualized approach is described in the original randomized trial. [KEYNOTE-942 in The Lancet](https://pubmed.ncbi.nlm.nih.gov/38246194/)

Pembrolizumab contributes a complementary mechanism: it blocks PD-1, a checkpoint that can restrain the activity of cancer-fighting T cells. The vaccine aims to improve recognition, while checkpoint inhibition helps immune cells act on that recognition. This explains why researchers tested the combination against pembrolizumab itself. The comparison asks whether adding the vaccine improves an established treatment. [National Cancer Institute: immune checkpoint inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

The word vaccine can be confusing in this setting. Cancer treatment vaccines target cancer-related antigens in people with a cancer diagnosis. In the postoperative setting, the objective is to prevent recurrence from cancer cells that may remain after visible disease has been removed. This approach is different from vaccination against an infection that can later cause cancer. [National Cancer Institute: cancer treatment vaccines](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines)

What do patients need to know about benefits and risks?

Recurrence-free survival measures the time before cancer returns or death occurs; overall survival measures how long patients remain alive. Improvement in one does not automatically establish improvement in the other. The five-year phase 2b analysis reported an encouraging overall-survival trend, but its confidence interval included the possibility of no benefit. That uncertainty prevents a firm conclusion that the combination extends life. [Five-year follow-up results](https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/)

Treatment also has risks. In the original phase 2b publication, grade 3 or higher treatment-related adverse events occurred in 25% of patients receiving the combination and 18% receiving pembrolizumab alone. These figures describe the entire treatment regimen and cannot all be attributed to the vaccine. They also should not be substituted for the phase 3 safety results. [Original trial safety findings](https://pubmed.ncbi.nlm.nih.gov/38246194/)

For patients considering treatment after surgery, the practical discussion begins with melanoma stage, recurrence risk, previous treatment and suitability for immunotherapy. Established postoperative options already exist for selected patients, and their benefits must be weighed against potential toxicity. Patients can discuss investigational vaccine studies with their oncology team while continuing decisions about currently available care. [National Cancer Institute: melanoma research and postoperative treatment](https://www.cancer.gov/types/skin/research)